<DOC>
	<DOC>NCT02749383</DOC>
	<brief_summary>This study is a Phase II, single center, randomized, double-blind, placebo-controlled study in male and female subjects, aged ≥ 19 years with mild to moderate seborrheic dermatitis of the face. All subjects will receive BID topical applications of PAC-14028 cream or vehicle for up to 4 weeks.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Seborrheic</mesh_term>
	<criteria>Male or female patients aged between 19 and 65 years old Clinical diagnosis of seborrheic dermatitis in the facial area with Erythema severity ≥ 2 and Scaling severity ≥ 2 IGE (Investigator's Global Evaluation) Score 2 or 3 Patients with psoriasis, atopic dermatitis, facial acne, rosacea or perioral dermatitis Patients who have been infected with bacteria, fungi, virus and animal infectious disease on the facial area Patients who were administered topical antifungal agents, steroids, retinoids, or calcineurin suppressants for the treatment of seborrheic dermatitis within the last 2 weeks Patients who were administered systemic antifungal agents, steroids, retinoids, or immunosuppressants for the treatment of seborrheic dermatitis within the last 4 weeks Patients who were administered local antibiotics for the treatment of seborrheic dermatitis within the last 4 weeks Pregnant women, breastfeeding women or women of childbearing potential or women who are planning a pregnancy during the study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>